npj Breast Cancer

Article	Citations
Biological correlates associated with high-risk breast cancer patients identified using a computational method	309
Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer	171
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab	169
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer	155
Circulating tumor cells in breast cancer: clinical validity and utility	143
Reversion of breast epithelial polarity alterations caused by obesity	121
Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer	101
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function	92
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools	88
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	86
The clinical and molecular significance associated with STING signaling in breast cancer	74
Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families	69
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer	66
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?	64
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women	63
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer	62
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study	61
UACA locus is associated with breast cancer chemoresistance and survival	58
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6	54
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells	54
Subclonal heterogeneity and evolution in breast cancer	50
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients	49
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer	49
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models	49
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases	48

Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy	46
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women	44
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer	43
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer	42
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses	42
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer	41
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial	39
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors	38
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients	38
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial	37
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation	37
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape	36
International survey on invasive lobular breast cancer identifies priority research questions	35
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers	35
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers	35
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ	32
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer	31
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer	31
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer	30
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	30
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment	30
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade	30
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning	29
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients	29
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification	29
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB	28
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition	28
PARP inhibition in breast cancer: progress made and future hopes	27
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	27
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women	27
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing	27
Immunotherapy for early triple negative breast cancer: research agenda for the next decade	26
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression	26
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	26
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor	26
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	26
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis	25
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning	25
Clinical outcomes of de novo metastatic HER2-low breast cancer: a National Cancer Database Analysis	25
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence	24
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer	24
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study	24
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer	24
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	24
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	24
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology	23
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis	23
Racial discrimination among women seeking breast cancer care	23
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer	23
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes	23

Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer	23
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)	23
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study	22
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC	22
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies	22
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer	22
Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer	22
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR	21
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	21
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study	21
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects	20
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial	20
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1	20
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial	19
Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study	19
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study	19
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis	19
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer	19
Management of the axilla in T1-2N1 breast cancer	18
Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer	18
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer	18
Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences	18
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study	18
Overexpression of COL11A1 confers tamoxifen resistance in breast cancer	17
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research	17
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial	17
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer	17
Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer	17
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry	17
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy	17
Reporting on invasive lobular breast cancer in clinical trials: a systematic review	17
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response	17
Survival outcomes after omission of surgery for ductal carcinoma in situ	17
Plasma C-peptide mammographic features and risk of breast cancer	17
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer	17
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors	16
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence	16
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis	15
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer	15
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer	15
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer	15
Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients	15
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer	15
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes	15
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes	15
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays	15
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer	15
Sustained lymphocyte decreases after treatment for early breast cancer	15
A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes	15
Temporal evolution of breast cancer brain metastases treatments and outcomes	14
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab	14
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer	14
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study	14
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis	14
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases	14
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer	14
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer	14
EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology	14
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial	14
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study	14
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study	13
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models	13
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy	13
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan	13
GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy	13
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity	13
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies	13
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients	13
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer	13
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer	13
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer	13
Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer	13
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer	13
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer	13
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study	13
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan	13
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice	12
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer	12
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature	12

Efficacy of FERscore in predicting sensitivity to ferroptosis inducers in breast cancer	12
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib	12
Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study	12
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer	12
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer	12
Understanding metastasis mixed-treatment responses through genomic analyses	12
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality	12
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	12
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer	12
Circulating tumor DNA validity and potential uses in metastatic breast cancer	12
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer	12
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment	12
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study	11
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer	11
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer	11
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors	11
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling	11
Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness	11
Author Correction: Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer	11
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)	11
Evaluation of a mobile behavior change program for weight loss in breast cancer survivors	11
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy	11
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer	10
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer	10
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center	10
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer	10
Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome	10
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study	10
Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial	10
Post-diagnosis weight trajectories and mortality among women with breast cancer	10
Automated percent mammographic density, mammographic texture variation, and risk of breast cancer: a nested case-control study	10
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-1	10
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling	10
The central role of pathology labs in breast cancer precision oncology: a call for action	10
A multi-model approach integrating whole-slide imaging and clinicopathologic features to predict breast cancer recurrence risk	10
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination	9
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality	9
Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment	9
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	9
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge	9
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours	9
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer	9
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing	9
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression	9
A careful reassessment of anthracycline use in curable breast cancer	9
Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates	9
Author Correction: Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer	9
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion	9
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer	9
Kataegis in clinical and molecular subgroups of primary breast cancer	9
Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing	9
Artificial intelligence in breast pathology – dawn of a new era	9
Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer	9
Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer	9
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer	8
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer	8
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis	8
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis	8
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers	8
Connected-UNets: a deep learning architecture for breast mass segmentation	8
Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women	8
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer	8
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts	8
Is conservative management of ductal carcinoma in situ risky?	8
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis	8
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	8
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer	8
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer	8
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer	8
The accuracy of magnetic resonance imaging in predicting the size of pure ductal carcinoma in situ: a systematic review and meta-analysis	8
Allostatic load as a predictor of postoperative complications in patients with breast cancer	8
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy	8
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin	8
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers	8
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models	7
Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers	7
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab	7
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings	7
Mammographic texture features associated with contralateral breast cancer in the WECARE Study	7
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study	7
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics	7
Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative	7
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer	7
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer	7
CBD-oil as a potential solution in case of severe tamoxifen-related side effects	7
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study	7
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer	7
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer	7
Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis	7
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab	6
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab	6
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors	6
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial	6
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer	6
Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy	6